Originally published byEU-Startups
Sightera Biosciences, an Antwerp-based AI drug discovery startup and spin-off from the University of Antwerp (UA) and Antwerp University Hospital (UZA), today announced the closing of a €3 million pre-Seed financing led by Entourage, Anacura and QBIC. The company plans to use this funding to expand the team, accelerate the expansion of its AI-native drug […]
The post Antwerp’s Sightera Biosciences raises €3 million to scale its patient-derived AI drug discovery platform appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
ORiS secures €5 million to develop wireless power transmission systems for space and dual-use applications
7h ago
Burnham sparks backlash over reported plans to ditch DSIT
1d ago
'If you're not AI-native, you're not getting funded': European fintech's H1 funding figures
2h ago
Viking 1 landed on Mars 50 years ago
3h ago
15 anti-fraud startups to watch in 2026, according to investors
1d ago